{"prompt": "['Trelagliptin-4002', 'Page 11 of 66', 'Version 2.0', 'July 5, 2017', '50 mg is orally administered once weekly in patients', 'with moderate renal impairment.', 'The comparative drug (Daily DPP-4 inhibitor) group:', 'An inhibitor is orally administered at the dosage and', 'administration in the package inserts for each drug.', 'Duration of treatment:', 'Duration of evaluation:', '12 weeks', '16 weeks', '(Screening period: 4 weeks; treatment', 'period: 12 weeks)', 'Inclusion criteria:', 'Eligibility of study subjects shall be determined in accordance with the following criteria.', '1.', 'Patients diagnosed as type 2 diabetes.', '2.', 'Patients with a stable diet and exercise therapy only for at least 12 weeks prior to the start of the', 'screening period.', '3.', 'Patients who require a DPP-4 inhibitor treatment.', '4.', 'Patients with and <10.0 % at the start of the screening period.', '5. Patients who completed DTR-QOL questionnaire at the start of the screening period.', '6.', 'Patients who have receive less than 2 types of medication for treatment of comorbidities (such', 'as hypertension or dyslipidemia) at the start of the screening period (any number of daily', 'doses).', '7.', 'Patients who, in the opinion of the principal investigator or the investigator, are capable of', 'understanding the content of the clinical study and complying with the study protocol', 'requirements.', '8. Patients who can provide the written informed consent prior to the initiation of any study', 'procedures.', '9.', 'Patients aged >20 years at the time of informed consent.', '10. Outpatient.', 'Exclusion criteria:', 'Study subjects meeting any of the criteria below shall not be included in this study.', '1.', 'Patients who are receiving any oral anti-diabetic medication for the treatment of type 2 diabetes', 'at the start of the screening period.', '2.', 'Patients diagnosed as type 1 diabetes.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 12 of 66', 'Version 2.0', 'July 5, 2017', '3.', 'Patients with severe renal impairment or renal failure (e.g., eGFR <30 mL/min/1.73 m\u00b2 or on', 'dialysis).', '4.', 'Patients with serious heart disease or cerebrovascular disorder, or serious pancreatic, blood, or', 'other disease.', '5.', 'Patients with a history of gastrointestinal resection.', '6.', 'Patient with a proliferative diabetic retinopathy.', '7.', 'Patient with malignancy.', '8.', 'Patients with a history of hypersensitivity or allergy to DPP-4 inhibitors.', '9.', 'Pregnant, lactating or postmenopausal women.', '10. Patients who may need to add or discontinue concomitant medication or change the dose during', 'the study period.', '11. Patients who will require treatment with a prohibited concomitant medication during the study', 'period.', '12. Patients participating in other clinical studies.', '13. Patients assessed ineligible in the study by the principal investigator or the investigator.', 'ENDPOINTS:', '<Primary endpoint>', 'Change from baseline (Week 0) in total score for all question items in the DTR-QOL Questionnaire', 'at the end of the treatment period (Week 12).', '<Secondary endpoints>', 'Efficacy assessment:', 'Changes in the total score for each factor provided through the DTR-QOL Questionnaire', '[Factor 1: Burden on social activities and daily activities (13 questions in all), Factor 2: Anxiety', 'and dissatisfaction with treatment (8 questions in all), Factor 3: Hypoglycemia (4 questions in', 'all) and Factor 4: Treatment satisfaction (4 questions in all) at each assessment time point.', 'Change in the total score for all questions in the DTR-QOL Questionnaire at each assessment', 'time point.', 'Change in the total score for treatment satisfaction in the Diabetes Treatment Satisfaction', 'Questionnaire (DTSQ) at each assessment time point.', 'Changes in the total scores for all questions in the DTR-QOL Questionnaire and the total score', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 13 of 66', 'Version 2.0', 'July 5, 2017', 'for treatment satisfaction in the DTSQ, stratified by the following factors at the start of the', 'treatment period (Week 0) within each treatment group.', 'Use of medication for treatment of comorbidities', 'Number of daily doses of medication for treatment of comorbidities (<2 times or >2 times)', 'Total number of daily tablets of medication for treatment of comorbidities (<2 tablets or', '>2 tablets)', 'Number of doses of the study drug or comparative drug (once weekly, once daily or twice', 'daily)', 'Changes in the scores per question in the DTR-QOL Questionnaire at each assessment time', 'point.', 'Changes in the scores per question in the DTSQ at each assessment time point.', 'Safety assessment:', 'Adverse events', 'Incidence of hypoglycemia', 'Hospitalization for type 2 diabetes (duration and number, excluding educational hospitalization', 'without worsening of diabetes)', 'Other Endpoints>', 'Laboratory tests [HbA1c, fasting blood glucose, fasting insulin, fasting glucagon,', 'glycoalbumin, 1,5-AG, serum creatinine, urinary 8-OHdG (using a correction value of uric', 'creatinine (8-OHdG/creatinine)) and urinary creatinine]', 'Treatment compliance', 'The Basic Information on Study Subject (Your Basic Profile)', 'STATISTICAL ANALYSIS METHODS:', '<Analysis Sets>', 'Two analysis sets comprising the \"Full Analysis Set (FAS)\\' and the \"Safety Population\" will be', 'established. The FAS used as the main efficacy analysis set is defined as \"randomized subjects who', 'receive at least one dose of trelagliptin or daily DPP-4 inhibitor.\" The safety population is defined', 'as \"subjects who receive at least 1 dose of trelagliptin or daily DPP-4 inhibitor.\"', '<Primary endpoint>', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}